App-Quantinova.ai

Utilization of Natural Language Processing in Venous Thromboembolism Identification

Jonathan Avery - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Solid malignancies

N/A

Long-Term Outcomes in Patients with Idiopathic Portal Venous System Thrombosis (PVST) in a Limited Resource Setting. Should We Do an Extensive Thrombophilia Work-up?

Fernando Gil López - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

Protein C

Isolated Thrombocytopenia in Older Adults Is Associated with the Diagnosis of Hematologic Malignancy: A Population-Based Study

Abi Vijenthira - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

Dexamethasone

Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)

Noemie Gadaud - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Understanding the Treatment Preferences of Adults with Cancer

Prajwal Dhakal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data

Mahek Garg - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany

Peter Borchmann - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis

Mahek Garg - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Return to School Challenges Affecting Adolescent Recipients of Allogeneic Hematopoietic Cell Transplantation: A Qualitative Interview Study of Caregivers

Neel S. Bhatt - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Joaquin Martinez Lopez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

N/A

Patient Reported Experience with Fatigue, a Cross Sectional Study Examining Indolent and Aggressive Lymphomas

Olufunmilayo A Bamigbola - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Aaron S Rosenberg - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Lanthanum carbonate

Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - a Retrospective Health Claims Data Analysis

Peter Borchmann - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Rachel Burstein - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Assessing the Safety of Discharging Patients Receiving High-Dose Methotrexate with Levels Greater Than 0.1 Umol/L

Elaine Xiang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

sodium bicarbonate

Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma

Fahrettin Covut - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Stagnation in Quality of Next-Generation Sequencing Assays for the Diagnosis of Hereditary Hematopoietic Malignancies

Gregory W. Roloff - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

TP53

Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Dianne Pulte - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cytarabine liposomal

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Pamela C Egan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Beliefs, Goals, Preferences, and Top Concerns of Patients with Acute Myeloid Leukemia at a Treatment Decision Visit

Omer H Jamy - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts